Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Auteur de référence en rhumatologie
29 articles scientifiques publiés — un praticien à la pointe de la recherche
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
JAMA internal medicine · 2023
ImportanceTo our knowledge, no randomized clinical trial has compared the invasive and conservative strategies in frail, older patients with non–ST-segment elevation acute myocardial infarction (NSTEMI).ObjectiveTo compare outcomes of invasive and conservative strategies in frail, older patients with NSTEMI at 1 year.Design, Setting, and ParticipantsThis multicenter randomized clinical trial was conducted at 13 Spanish hospitals between July 7, 2017, and January 9, 2021, and included 167 older adult (≥70 years) patients with frailty (Clinical Frailty Scale score ≥4) and NSTEMI. Data analysis was performed from April 2022 to June 2022.InterventionsPatients were randomized to routine invasive (coronary angiography and revascularization if feasible; n = 84) or conservative (medical treatment with coronary angiography for recurrent ischemia; n = 83) strategy.Main Outcomes and MeasuresThe primary end point was the number of days alive and out of the hospital (DAOH) from discharge to 1 year. The coprimary end point was the composite of cardiac death, reinfarction, or postdischarge revascularization.ResultsThe study was prematurely stopped due to the COVID-19 pandemic when 95% of the calculated sample size had been enrolled. Among the 167 patients included, the mean (SD) age was 86 (5) years, and mean (SD) Clinical Frailty Scale score was 5 (1). While not statistically different, DAOH were about 1 month (28 days; 95% CI, −7 to 62) greater for patients managed conservatively (312 days; 95% CI, 289 to 335) vs patients managed invasively (284 days; 95% CI, 255 to 311; P = .12). A sensitivity analysis stratified by sex did not show differences. In addition, we found no differences in all-cause mortality (hazard ratio, 1.45; 95% CI, 0.74-2.85; P = .28). There was a 28-day shorter survival in the invasive vs conservatively managed group (95% CI, −63 to 7 days; restricted mean survival time analysis). Noncardiac reasons accounted for 56% of the readmissions. There were no differences in the number of readmissions or days spent in the hospital after discharge between groups. Neither were there differences in the coprimary end point of ischemic cardiac events (subdistribution hazard ratio, 0.92; 95% CI, 0.54-1.57; P = .78).Conclusions and RelevanceIn this randomized clinical trial of NSTEMI in frail older patients, there was no benefit to a routine invasive strategy in DAOH during the first year. Based on these findings, a policy of medical management and watchful observation is recommended for older patients with frailty and NSTEMI.Trial RegistrationClinicalTrials.gov Identifier: NCT03208153
JAMA network open · 2024
ImportanceThe MOSCA-FRAIL randomized clinical trial compared invasive and conservative treatment strategies in patients with frailty with non–ST-segment elevation myocardial infarction (NSTEMI). It showed no differences in the number of days alive and out of the hospital at 1 year.ObjectiveTo assess the outcomes of the MOSCA-FRAIL trial during extended follow-up.Design, Setting, and ParticipantsThe MOSCA-FRAIL randomized clinical trial was conducted at 13 hospitals in Spain between July 7, 2017, and January 9, 2021, and included 167 adults (aged ≥70 years) with frailty (Clinical Frailty Scale score ≥4) and NSTEMI. In this preplanned secondary analysis, follow-up was extended to January 31, 2023. Data analysis was performed from April 5 to 29, 2023, using the intention-to-treat principle.InterventionsPatients were randomized to a routine invasive (coronary angiography and revascularization if feasible [n = 84]) or a conservative (medical treatment with coronary angiography only if recurrent ischemia [n = 83]) strategy.Main outcomes and measuresThe primary end point was the difference in restricted mean survival time (RMST). Secondary end points included readmissions for any cause, considering recurrent readmissions.ResultsAmong the 167 patients included in the analysis, the mean (SD) age was 86 (5) years; 79 (47.3%) were men and 88 (52.7%) were women. A total of 93 deaths and 367 readmissions accrued. The RMST for all-cause death over the entire follow-up was 3.13 (95% CI, 2.72-3.60) years in the invasive and 3.06 (95% CI, 2.84-3.32) years in the conservative treatment groups. The RMST analysis showed inconclusive differences in survival time (invasive minus conservative difference, 28 [95% CI, −188 to 230] days). Patients under invasive treatment tended to have shorter survival in the first year (−28 [95% CI, −63 to 7] days), which improved after the first year (192 [95% CI, 90-230] days). Kaplan-Meier mortality curves intersected, displaying higher mortality to 1 year in the invasive group that shifted to a late benefit (landmark analysis hazard ratio, 0.58 [95% CI, 0.33-0.99]; P = .045). Early harm was more evident in the subgroup with a Clinical Frailty Scale score greater than 4. No differences were found for the secondary end points.Conclusions and RelevanceIn this extended follow-up of a randomized clinical trial of patients with frailty and NSTEMI, an invasive treatment strategy did not improve outcomes at a median follow-up of 1113 (IQR, 443-1441) days. However, a differential distribution of deaths was observed, with early harm followed by later benefit. The phenomenon of depletion of susceptible patients may be responsible for this behavior.Trial registrationClinicalTrials.gov Identifier: NCT03208153
JAMA · 2025
ImportanceThere are no useful treatments to prevent the development of severe complications of liver cirrhosis. Simvastatin and rifaximin have shown beneficial effects in liver cirrhosis.ObjectiveTo assess whether simvastatin combined with rifaximin improves outcomes in patients with decompensated cirrhosis.Design, Setting, and ParticipantsDouble-blind, placebo-controlled, phase 3 trial conducted among patients with decompensated cirrhosis in 14 European hospitals between January 2019 and December 2022. The last date of follow-up was December 2022.InterventionsPatients were randomly assigned to receive simvastatin, 20 mg/d, plus rifaximin, 1200 mg/d (n = 117), or identical-appearing placebo (n = 120) for 12 months in addition to standard therapy, stratified according to Child-Pugh class B or C.Main Outcomes and MeasuresThe primary end point was incidence of severe complications of liver cirrhosis associated with organ failure meeting criteria for acute-on-chronic liver failure. Secondary outcomes included transplant or death and a composite end point of complications of cirrhosis (ascites, hepatic encephalopathy, variceal bleeding, acute kidney injury, and infection).ResultsAmong the 237 participants randomized (Child-Pugh class B: n = 194; Child-Pugh class C: n = 43), 72% were male and the mean age was 57 years. There were no differences between the 2 groups in terms of development of acute-on-chronic liver failure (21 [17.9%] vs 17 [14.2%] patients in the treatment and placebo groups, respectively; hazard ratio, 1.23; 95% CI, 0.65-2.34; P = .52); transplant or death (22 [18.8%] vs 29 [24.2%] patients in the treatment and placebo groups, respectively; hazard ratio, 0.75; 95% CI, 0.43-1.32; P = .32); or development of complications of cirrhosis (50 [42.7%] vs 55 [45.8%] patients in the treatment and placebo groups, respectively; hazard ratio, 0.93; 95% CI, 0.63-1.36; P = .70). Incidence of adverse events was similar in both groups (426 vs 419; P = .59), but 3 patients in the treatment group (2.6%) developed rhabdomyolysis.Conclusions and RelevanceThe addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis.Trial RegistrationClinicalTrials.gov Identifier: NCT03780673
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Early intervention in psychiatry · 2026 · Journal Article
Kim HJ, Welikson T, McCarthy JM, Millman ZB, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2025 · Journal Article
G A, C G, C J M, B L, et al.
Computational biology and chemistry · 2025 · Journal Article
Innasi Lineta P, Carol JJ
The Medical journal of Malaysia · 2025 · Journal Article
Idris MS, Ling DY, Carol FF, Ramli ARH
Schizophrenia research · 2023 · Journal Article
Gupta T, Horton WS, Haase CM, Carol EE, et al.
Tropical medicine and health · 2023 · Journal Article
Littlejohns A, Please H, Musasizi R, Murdoch S, et al.
Annals of the rheumatic diseases · 2023 · Letter
C SK, Ahmed S, Shenoy V, Menon AR, et al.
Revista espanola de cardiologia (English ed.) · 2025 · Journal Article
Sanchis J, Bueno H, García-Blas S, Gómez-Hospital JA, et al.
JAMA · 2025 · Journal Article
Pose E, Jiménez C, Zaccherini G, Campion D, et al.
JAMA network open · 2024 · Journal Article
Sanchis J, Bueno H, García-Blas S, Alegre O, et al.
Pediatric dermatology · 2025 · Journal Article
Gomes LLA, Silva GS, Carol HA, Subhadarshani S, et al.
European journal of pediatrics · 2024 · Journal Article
Yıldız Ç, Küçükali B, C SSB, Şenol PE, et al.
Current opinion in rheumatology · 2023 · Review
Carol HA, Chauvin NA, Weiss PF
Cureus · 2025 · Case Reports
C P, Ann Jose J, Verma G, Priya V L, et al.
Cureus · 2024 · Case Reports
Ramanan A, Balasubramanian V, C R, Sami P
JBJS case connector · 2024 · Case Reports
C A, Raju A, Meleppuram JJ, Nair AV, et al.
Journal of geriatric psychiatry and neurology · 2026 · Journal Article
Sirna C, Panse A, Alexopoulos P, Carol E, et al.
Revista espanola de cardiologia (English ed.) · 2025 · Journal Article
Sanchis J, Bueno H, García-Blas S, Gómez-Hospital JA, et al.
Journal of geriatric cardiology : JGC · 2024 · Journal Article
Ariza-Solé A, Andrés Bermeo J, Formiga F, Bueno H, et al.
Psychiatric services (Washington, D.C.) · 2025 · Journal Article
Millman ZB, Gerken AT, Carol EE, Van Kirk NP, et al.
Psychological services · 2024 · Journal Article
McCarthy JM, Hudson JI, Carol EE, Kuller AM, et al.
Community mental health journal · 2023 · Journal Article
Van Overloop E, Arms-Chavez C, Carol RN, LoBello SG
European journal of pediatrics · 2024 · Journal Article
Yıldız Ç, Küçükali B, C SSB, Şenol PE, et al.
Journal of the American Academy of Dermatology · 2025 · Journal Article
Shen CZ, Carol H, Feng R, Hill A, et al.
Journal of geriatric cardiology : JGC · 2024 · Journal Article
Ariza-Solé A, Andrés Bermeo J, Formiga F, Bueno H, et al.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2024 · Journal Article
Tébar D, Carrillo X, García Del Blanco B, Gómez-Hospital JA, et al.
Advances in protein chemistry and structural biology · 2026 · Journal Article
Loganathan T, Madhulekha S, Zayed H, C GPD
Cureus · 2024 · Case Reports
Ramanan A, Balasubramanian V, C R, Sami P
Cureus · 2025 · Case Reports
Lakshme I, C A, Senthil N, Pandurangan V
Cureus · 2026 · Case Reports
R S, Nanda M S, Adalarasan S, Subramanian Y, et al.
EClinicalMedicine · 2023 · Journal Article
Pinar-Martí A, Gignac F, Fernández-Barrés S, Romaguera D, et al.
JAMA internal medicine · 2023 · Journal Article
Sanchis J, Bueno H, Miñana G, Guerrero C, et al.
Transplant international : official journal of the European Society for Organ Transplantation · 2023 · Journal Article
Nel I, Parmentier C, Dehoux L, Minier M, et al.